ArticleIBRO neuroscience reports2025
Rethinking parvalbumin: From passive marker to active modulator of hippocampal circuits.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Chloride Homeostasis Failure in Human Disease: KCC2/NKCC1 Microdomain Dysfunction as a Driver of Cortical Network Collapse.International journal of molecular sciences · 2026Review
- Sex-specific changes in the hippocampal proteome of Negr1Biology of sex differences · 2026Article
- Review
- Parvalbumin interneurons: the dark and bright sides of a key playmaker of neural circuits and behavior.Frontiers in cellular neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parvalbumin (PV)-expressing interneurons are critical regulators of neural circuit dynamics, and for decades, the PV protein has served as their definitive molecular marker. This review confronts a central, yet underappreciated, paradox: the incongruity of a kinetically slow Ca²⁺ buffer (PV) being the defining feature of the brain's fastest-spiking neurons. We synthesize evidence from molecular biophysics, genetics, in vivo circuit analysis, and disease modeling to dissect the dual role of PV as both a cellular marker and an active functional regulator. We argue that PV's slow kinetics are not a coincidence but a crucial adaptation that shapes short-term synaptic plasticity, protects against metabolic stress during high-frequency firing, and allows the circuit to shift between states of plasticity and stability. This reframing resolves the paradox by demonstrating how a "slow" molecule is essential for "fast" neuronal function. Furthermore, we highlight that dysfunction of the PV system is a convergent hub of pathology in numerous neurological and psychiatric disorders, including schizophrenia, epilepsy, and Alzheimer's disease. By moving beyond its identity as a passive marker, we establish PV as an active modulator of neural computation and a potential therapeutic target for restoring network function in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.